BCM
MREO

Bridgeway Capital Management’s Mereo BioPharma MREO Stock Holding History

Bridgeway Capital Management’s Portfolio MREO Stock Details MREO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-15,961
Closed -$46K – 1367
2019
Q3 		$46K Sell
15,961
-753
-5% -$2.28K ﹤0.01% 1278
2019
Q2 		$40K Buy
+16,714
New +$73.1K ﹤0.01% 1285

Other funds holding MREO

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
DMPV
Delphi Management Partners VIII San Mateo, California $138M AUM 56.74% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CL
CSS LLC Chicago, Illinois $2.09B AUM 59.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Bridgeway Capital Management's MREO Position: Q4 2019 in Review

Bridgeway Capital Management sold out of Mereo BioPharma (MREO) in Q4 2019, closing a stake of 15,961 shares — an estimated $46K sold.

Bridgeway Capital Management first reported a position in MREO in Q2 2019 and held it in 2 quarters. The position peaked at $46K in Q3 2019. 14 funds tracked by Wall St. Rank hold MREO as of Q4 2019.

  • Bridgeway Capital Management reported no remaining Mereo BioPharma position as of Q4 2019 after selling out during the quarter.
  • Bridgeway Capital Management sold 15,961 Mereo BioPharma shares in Q4 2019, an estimated $46K.
  • Bridgeway Capital Management first reported a position in Mereo BioPharma in Q2 2019 and held it in 2 quarters.
  • Bridgeway Capital Management's Mereo BioPharma position peaked at $46K in Q3 2019.
  • 14 funds tracked by Wall St. Rank held Mereo BioPharma as of Q4 2019.

Based on Bridgeway Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.